TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.050
0.00 (0.00%)
At close: Sep 14, 2026, 4:00 PM EDT
2.087
+0.037 (1.80%)
Pre-market: Sep 15, 2026, 7:56 AM EDT
TuHURA Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.
-
The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.